Prediction: This Healthcare Stock Could Soar by 40% in 2026

• Novo Nordisk had a unsmooth agelong successful 2025 that yet led to it "firing" its CEO.

• The caller Wegovy pill looks similar a game-changer for the pharmaceutical giant.

• That bodes good for a banal with a compelling valuation.

• 10 stocks we similar amended than Novo Nordisk ›

Novo Nordisk (NYSE: NVO) fundamentally made the obesity cause marketplace the surging maturation accidental it is contiguous with the viral occurrence of its GLP-1 agonists, Ozempic for Type 2 diabetes and Wegovy for chronic value management. But the institution deed a pugnacious stretch, marred by contention from Eli Lilly and telehealth companies selling generic products. Things got truthful atrocious that Novo Nordisk efficaciously ousted its CEO successful May of past year. In that time, the banal has plunged, losing much than fractional of its worth since peaking successful mid-2024.

Novo Nordisk's banal has travel live recently, and it's nary fluke. Here is wherefore I foretell that Novo Nordisk banal could soar by 40% this year.

Novo Nordisk precocious made headlines by launching its recently FDA-approved Wegovy pill successful aboriginal January. Wegovy and different obesity drugs person historically been subcutaneous (administered beneath the skin), requiring patients to inject them. The caller pill is the aforesaid cause arsenic Wegovy, but successful an oral tablet. It's acold much convenient for astir patients, particularly those who don't similar needles.

The company's caller CEO has besides been assertive successful pushing the Wegovy pill to the market. Novo Nordisk came acceptable with an ample proviso and has partnered with Amazon, Costco Wholesale, and different user channels to marque the pill arsenic accessible arsenic it can. The institution precocious reported astir 3,100 prescriptions filled successful the archetypal week since motorboat and 8,000 by the 2nd week.

Given that Wegovy is presently the lone pill-form cause of its benignant connected the market, Novo Nordisk could spot its gross maturation accelerate implicit the adjacent fewer quarters arsenic the pill's motorboat continues. News of the pill's aboriginal occurrence has already lifted Novo Nordisk banal disconnected its caller lows.

What mightiness that mean for investors? Consider that Novo Nordisk has traded astatine an mean price-to-earnings (P/E) ratio of 27 implicit the past decade. Today, shares inactive commercialized astatine conscionable 18 times earnings. It doesn't look similar a agelong that renewed religion successful the institution could assistance that valuation backmost person to its semipermanent norms.

Just to beryllium conservative, 1 could adjacent presume a somewhat little valuation, accidental a P/E ratio of 25. The statement among Wall Street analysts is that Novo Nordisk volition gain astir $3.49 per stock this year. Applying that P/E ratio results successful a stock terms of $87.25. That's astir 40% supra the stock's existent stock price.